Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | SOLAR-1: alpelisib plus fulvestrant for advanced breast cancer

Fabrice André • 20 Oct 2018
ESMO 2018
Breast Cancer Alpelisib Fulvestrant
SOLAR-1

The latest from SOLAR-1 (NCT02437318), assessing alpelisib plus fulvestrant for advanced breast cancer that progressed on or after aromatase inhibitor treatment., is presented by Fabrice André, MD, PhD, of the Gustave Roussy Institute, Villejuif, France, here at the breast cancer press briefing at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, which showcased the latest updates for three major Phase III clinical trials.

More from Fabrice André

2:17
CANTO: improving the quality of life of women treated for localized breast cancer
Fabrice André • 11 Sep 2022
1:57
monarcHER: final OS results of abemaciclib in HR+, HER+ breast cancer
Fabrice André • 11 Sep 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals